fls.txt
The Company undertakes no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.


item1.txt
See notes to unaudited condensed consolidated financial statements.
See notes to unaudited condensed consolidated financial statements.
See notes to unaudited condensed consolidated financial statements.
See notes to unaudited condensed consolidated financial statements.
The accompanying condensed consolidated financial statements include the accounts of Scientific Industries, Inc., Altamira Instruments, Inc. (“Altamira”), a Delaware corporation and wholly-owned subsidiary, Scientific Bioprocessing, Inc. (“SBI”), a Delaware corporation and wholly-owned subsidiary, and Scientific Packaging Industries, Inc., an inactive wholly-owned subsidiary (all collectively referred to as the “Company”).
All material intercompany balances and transactions have been eliminated.
In February 2016, the FASB issued ASU No.
The FASB issued this update to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements.
The updated guidance is effective for annual periods beginning after December 15, 2018, including interim periods within those fiscal years.
Early adoption of the update is permitted.
This update provides guidance on how to record eight specific cash flow issues.
This update is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years.
The Company is a fiscal-year end taxpayer and is required to use a blended statutory federal tax rate, inclusive of the Federal rate change enacted on December 22, 2017 to compute its effective rate for the three and six months ended December 31, 2017.
Approximately 31% and 55% of net benchtop laboratory equipment sales (48% and 30% of total revenues) for the three month periods ended December 31, 2017 and 2016, respectively, were derived from the Company’s main product, the Vortex-Genie 2 mixer, excluding accessories.
Approximately 12% and 21% of total benchtop laboratory equipment sales (19% and 11% of total revenues) were derived from the Torbal Scales Division for the three months ended December 31, 2017 and 2016, respectively.


item2.txt
The Company reflected income before income tax expense of $16,400 for the three months ended December 31, 2017 compared to $64,800 for the three months ended December 31, 2016, primarily due to lack of sales of catalyst research instruments during the period and product development expenses for a new automated pill counter for the Laboratory Equipment Operations.
The Company reflected a loss before income tax benefit of $290,100 for the six months ended December 31, 2017 compared to $4,700 for the six months ended December 31, 2016 mainly due to decreased catalyst research instrument sales and product development costs as previously discussed.
As of December 31, 2017, the order backlog for catalyst research instruments was $752,500, all of which is expected to be shipped during fiscal year ending June 30, 2018, compared to $397,300 as of December 31, 2016.
General and administrative expenses for the three months ended December 31, 2017 amounted to $407,900 compared to $409,200 for the three months ended December 31, 2016.
Selling expenses for the three months ended December 31, 2017 decreased $9,600 (4.3%) to $214,600 from $224,200 for the three months ended December 31, 2016, due to lower sales related expenses for the Catalyst Research Instruments Operations.
Research and development expenses increased by $27,900 (26.6%) to $132,900 for the three months ended December 31, 2017 compared to $105,000 for the three months ended December 31, 2016, primarily due to increased new product development costs incurred by the Benchtop Laboratory Equipment Operations related to the Torbal Scales Division.
Total other income decreased by $2,200 (26.5%) from $8,300 for the three months ended December 31, 2016 to $6,100 for the three months ended December 31, 2017 due to lower interest on its investment securities.
The overall gross profit percentage for the six months ended December 31, 2017 was 38.4% compared to 34.5% for the six months ended December 31, 2016 as a result of the Benchtop Laboratory Equipment Operations (which is sold at higher margins) consisting of a higher percentage of total sales for the year.
General and administrative expenses for the six months ended December 31, 2017 increased slightly by $14,700 (1.8%) to $836,300 compared to $821,600 for the six months ended December 31, 2016.
Selling expenses for the six months ended December 31, 2017 decreased $25,300 (5.7%) to $415,600 from $440,900 for the six months ended December 31, 2016, due to lower sales related expenses for the Catalyst Research Instruments Operations.
Total other income decreased by $7,300 (53.3%) from $13,700 for the six months ended December 31, 2016 to $6,400 for the six months ended December 31, 2017 due to lower interest on its investment securities and miscellaneous income items.


item4.txt
Evaluation of Disclosure Controls and Procedures.


